NCT01546103

Brief Summary

The purpose of this research study is to determine whether taking vitamin D, every day, over a 12 week period will improve the vitamin D status, risks for poor heart health, risks for developing type 2 diabetes, and/or muscle strength in overweight, African American teenagers with low vitamin D levels.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 4, 2012

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 7, 2012

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
Last Updated

January 23, 2013

Status Verified

January 1, 2013

Enrollment Period

1.1 years

First QC Date

January 4, 2012

Last Update Submit

January 22, 2013

Conditions

Keywords

Vitamin D deficiency

Outcome Measures

Primary Outcomes (1)

  • Serum 25OHD before and after treatment

    The analysis will be an intention-to-treat method in which subjects are assumed to obtain all vitamin D supplements from the study and from no other sources, and all subjects are assumed to comply with their assigned dose and daily use. For the main contrasts of interest (5000 IU vs 1000 IU doses as well as serum 25OHD concentrations), we propose a longitudinal mixed effects model with time measurements at 0 and 12 weeks.

    12 weeks

Secondary Outcomes (9)

  • Adiponectin level comparison

    12 weeks

  • Lipid panel comparison

    12 weeks

  • Lipoprotein subclass particles comparison

    12 weeks

  • High-sensitivity C-Reactive Protein (hsCRP) comparison

    12 weeks

  • Insulin level comparison

    12 weeks

  • +4 more secondary outcomes

Study Arms (2)

Vitamin D3 supplementation of 1000 IU

ACTIVE COMPARATOR
Dietary Supplement: Cholecalciferol

Vitamin D3 supplementation of 5000 IU

ACTIVE COMPARATOR
Dietary Supplement: Cholecalciferol

Interventions

CholecalciferolDIETARY_SUPPLEMENT

1000 IU by mouth, once daily for 3 months.

Also known as: Vitamin D
Vitamin D3 supplementation of 1000 IU

Eligibility Criteria

Age12 Years - 17 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • African American
  • Obese \[body mass index (BMI) greater than or equal to 95th percentile for age and sex\]
  • Pubertal (Tanner Stage greater than 1)
  • OHD less than 20 ng/mL (for treatment phase); if 25OHD is greater than or equal to 20 ng/mL, only baseline data will be obtained.
  • Committed to adherence to supplementation and study completion

You may not qualify if:

  • Pregnancy
  • Chronic medical conditions or medications use that can affect growth, nutrition, bone health, vitamin D metabolism, glucose, or insulin sensitivity
  • Known history of hypercalcemia or hypercalciuria
  • Non-English speaking, as assessments are available only in English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Vitamin D Deficiency

Interventions

CholecalciferolVitamin D

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsSecosteroidsMembrane LipidsLipids

Study Officials

  • Sheela N Magge, MD, MSCE

    Children's Hospital of Philadelphia

    PRINCIPAL INVESTIGATOR
  • Andrea Kelly, MD, MSCE

    Children's Hospital of Philadelphia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 4, 2012

First Posted

March 7, 2012

Study Start

August 1, 2011

Primary Completion

September 1, 2012

Study Completion

September 1, 2012

Last Updated

January 23, 2013

Record last verified: 2013-01

Locations